Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to $1000.0.

  • Benitec Biopharma's Change in Accured Expenses rose 11111.11% to $1000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was -$81000.0, marking a year-over-year decrease of 30769.23%. This contributed to the annual value of -$81000.0 for FY2025, which is 30769.23% down from last year.
  • According to the latest figures from Q2 2025, Benitec Biopharma's Change in Accured Expenses is $1000.0, which was up 11111.11% from -$159000.0 recorded in Q1 2025.
  • Over the past 5 years, Benitec Biopharma's Change in Accured Expenses peaked at $66000.0 during Q2 2021, and registered a low of -$159000.0 during Q1 2025.
  • Over the past 5 years, Benitec Biopharma's median Change in Accured Expenses value was $11000.0 (recorded in 2022), while the average stood at $11500.0.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 73333.33% in 2023, then plummeted by 805000.0% in 2025.
  • Over the past 5 years, Benitec Biopharma's Change in Accured Expenses (Quarter) stood at $3000.0 in 2021, then surged by 100.0% to $6000.0 in 2022, then surged by 733.33% to $50000.0 in 2023, then increased by 22.0% to $61000.0 in 2024, then plummeted by 98.36% to $1000.0 in 2025.
  • Its Change in Accured Expenses was $1000.0 in Q2 2025, compared to -$159000.0 in Q1 2025 and $61000.0 in Q4 2024.